Iovance Biotherapeutics, Inc. (IOVA)

12.03 +0.39 (+3.35%) 收市：04:00PM EDT

Iovance Biotherapeutics, Inc.

825 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 260 7120
https://www.iovance.com

版塊: Healthcare
行業: Biotechnology
全職員工: 557

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Frederick G. Vogt Esq., J.D., Ph.D.	Interim CEO, President, General Counsel & Corporate Secretary	1.39M	無	1974
Mr. Jean-Marc Bellemin M.B.A.	CFO, Principal Accounting Officer & Treasurer	932.2k	無	1973
Dr. Igor P. Bilinsky	Chief Operating Officer	932.2k	無	1973
Dr. Friedrich Graf Finckenstein M.D.	Chief Medical Officer	1.06M	無	1967
Ms. Sara Pellegrino	Vice President of Investor Relations & Public Relations	無	無	無
Ms. Tracy Winton	Senior Vice President of Human Resources	無	無	無
Mr. Howard B. Johnson M.B.A.	Chief Business Officer	無	無	1960
Mr. James Ziegler M.B.A.	Executive Vice President of Commercial	無	無	無
Dr. Raj K. Puri M.D., Ph.D.	Executive VP of Regulatory Strategy & Translational Medicine	無	無	無
Mr. Brian Shew M.B.A.	Senior VP & Head of Digital and Information Technology	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

公司管治

截至 2024年4月1日 止，Iovance Biotherapeutics, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：7；董事會：6；股東權利：3；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。